Trial Profile

An exploratory study assessing IMC-2 for treatment of Long COVID-19

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Celecoxib+valacyclovir-Virios Therapeutics (Primary)
Indications Fatigue; Post acute COVID 19 syndrome
Focus Adverse reactions; Proof of concept
Acronyms BHC Study 201; PASC

Most Recent Events

30 Oct 2024 According to Virios Therapeutics media release, Virios Therapeutics has changed its name to Dogwood Therapeutics.
18 Sep 2023 According to Virios media release, the Company's management team is currently focusing its attention on short-to-medium term operational priorities that are within the current operating budget includes providing an additional grant to conduct this study.
10 Aug 2023 Status changed from active, no longer recruiting to completed, according to Virios media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com